Evidence map›Paper›PMID 42558575›Full record

ArticleFrontiers in microbiology2026

Whole-genome sequencing reveals lineage-associated drug resistance and enables machine learning-based prediction in

Zelin Hao, Chao Wu, Yi Peng, Lijun Zhou, Jinyao Li, Xiaoguang Zou

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zelin HaoCollege of Life Science and Technology, Xinjiang University, Urumqi, China.
Chao WuDepartment of Infectious Diseases, First People's Hospital of Kashi, Kashi, China.
Yi PengThe Sixth People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Lijun ZhouSchool of Basic Medical Sciences, Xinjiang Medical University, Urumqi, China.
Jinyao LiCollege of Life Science and Technology, Xinjiang University, Urumqi, China.
Xiaoguang ZouSchool of Basic Medical Sciences, Xinjiang Medical University, Urumqi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Drug-resistant tuberculosis (TB) remains a major obstacle to global TB control, particularly in high-burden settings where timely detection of resistance is limited. This study aimed to integrate whole-genome sequencing and machine learning approaches to characterize the genomic architecture of drug resistance and develop predictive models for phenotypic resistance in clinical Methods: A total of 160 clinical Results: Phenotypic drug susceptibility testing classified 63 isolates (39.4%) as drug-sensitive, 67 (41.9%) as single-drug resistant (SDR), and 28 (17.5%) as multidrug-resistant (MDR), with a small number of extensively drug-resistant isolates. Resistance was dominated by first-line drugs, particularly isoniazid, streptomycin, and rifampicin. Phylogenetic analysis revealed non-random distribution of resistant isolates, with enrichment of MDR strains within Lineage 2 (Beijing lineage). Genomic profiling demonstrated a progressive increase in resistance-associated mutational burden from drug-sensitive to SDR and MDR isolates, characterized by accumulation of canonical mutations in Conclusion: This study demonstrates the potential utility of integrating phenotypic testing, whole-genome sequencing, and interpretable machine learning approaches for characterizing and predicting drug-resistant

Indexed as

antimicrobial resistancedrug-resistant tuberculosisgenomic epidemiologymachine learningMycobacterium tuberculosiswhole-genome sequencing

Identifiers

PMID42558575
PMCPMC13437962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.